Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
4 "Transcriptome"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Articles
Thyroid
Comparative Analysis of Driver Mutations and Transcriptomes in Papillary Thyroid Cancer by Region of Residence in South Korea
Jandee Lee, Seonhyang Jeong, Hwa Young Lee, Sunmi Park, Meesson Jeong, Young Suk Jo
Endocrinol Metab. 2023;38(6):720-729.   Published online November 6, 2023
DOI: https://doi.org/10.3803/EnM.2023.1758
  • 999 View
  • 45 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Radiation exposure is a well-known risk factor for papillary thyroid cancer (PTC). South Korea has 24 nuclear reactors in operation; however, no molecular biological analysis has been performed on patients with PTC living near nuclear power plants.
Methods
We retrospectively included patients with PTC (n=512) divided into three groups according to their place of residence at the time of operation: inland areas (n=300), coastal areas far from nuclear power plants (n=134), and nuclear power plant areas (n=78). After propensity score matching (1:1:1) by age, sex, and surgical procedure, the frequency of representative driver mutations and gene expression profiles were compared (n=50 per group). Epithelial-mesenchymal transition (EMT), BRAF, thyroid differentiation, and radiation scores were calculated and compared.
Results
No significant difference was observed in clinicopathological characteristics, including radiation exposure history and the frequency of incidentally discovered thyroid cancer, among the three groups. BRAFV600E mutation was most frequently detected in the groups, with no difference among the three groups. Furthermore, gene expression profiles showed no statistically significant difference. EMT and BRAF scores were higher in our cohort than in cohorts from Chernobyl tissue bank and The Cancer Genome Atlas Thyroid Cancer; however, there was no difference according to the place of residence. Radiation scores were highest in the Chernobyl tissue bank but exhibited no difference according to the place of residence.
Conclusion
Differences in clinicopathological characteristics, frequency of representative driver mutations, and gene expression profiles were not observed according to patients’ region of residence in South Korea.
Close layer
Thyroid
Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma
Jinsun Lim, Han Sai Lee, Jiyun Park, Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho, Young Shin Song
Endocrinol Metab. 2023;38(4):445-454.   Published online July 18, 2023
DOI: https://doi.org/10.3803/EnM.2023.1702
  • 1,643 View
  • 102 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Papillary thyroid carcinoma (PTC) can be classified into two distinct molecular subtypes, BRAF-like (BL) and RASlike (RL). However, the molecular characteristics of each subtype according to clinicopathological factors have not yet been determined. We aimed to investigate the gene signatures and tumor microenvironment according to clinicopathological factors, and to identify the mechanism of progression in BL-PTCs and RL-PTCs.
Methods
We analyzed RNA sequencing data and corresponding clinicopathological information of 503 patients with PTC from The Cancer Genome Atlas database. We performed differentially expressed gene (DEG), Gene Ontology, and molecular pathway enrichment analyses according to clinicopathological factors in each molecular subtype. EcoTyper and CIBERSORTx were used to deconvolve the tumor cell types and their surrounding microenvironment.
Results
Even for the same clinicopathological factors, overlapping DEGs between the two molecular subtypes were uncommon, indicating that BL-PTCs and RL-PTCs have different progression mechanisms. Genes related to the extracellular matrix were commonly upregulated in BL-PTCs with aggressive clinicopathological factors, such as old age (≥55 years), presence of extrathyroidal extension, lymph node metastasis, advanced tumor-node-metastasis (TNM) stage, and high metastasis-age-completeness of resection- invasion-size (MACIS) scores (≥6). Furthermore, in the deconvolution analysis of tumor microenvironment, cancer-associated fibroblasts were significantly enriched. In contrast, in RL-PTCs, downregulation of immune response and immunoglobulin-related genes was significantly associated with aggressive characteristics, even after adjusting for thyroiditis status.
Conclusion
The molecular phenotypes of cancer progression differed between BL-PTC and RL-PTC. In particular, extracellular matrix and cancer-associated fibroblasts, which constitute the tumor microenvironment, would play an important role in the progression of BL-PTC that accounts for the majority of advanced PTCs.
Close layer
Review Article
Thyroid
Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers
Seong-Keun Yoo, Young Shin Song, Young Joo Park, Jeong-Sun Seo
Endocrinol Metab. 2020;35(1):44-54.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.44
  • 7,250 View
  • 242 Download
  • 16 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   ePub   

Anaplastic thyroid cancer (ATC) is a lethal human cancer with a 5-year survival rate of less than 10%. Recently, its genomic and transcriptomic characteristics have been extensively elucidated over 5 years owing to advance in high throughput sequencing. These efforts have extended molecular understandings into the progression mechanisms and therapeutic vulnerabilities of aggressive thyroid cancers. In this review, we provide an overview of genomic and transcriptomic alterations in ATC and poorly-differentiated thyroid cancer, which are distinguished from differentiated thyroid cancers. Clinically relevant genomic alterations and deregulated signaling pathways will be able to shed light on more effective prevention and stratified therapeutic interventions for affected patients.

Citations

Citations to this article as recorded by  
  • The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
    Peter Y.F. Zeng, Stephenie D. Prokopec, Stephen Y. Lai, Nicole Pinto, Michelle A. Chan-Seng-Yue, Roderick Clifton-Bligh, Michelle D. Williams, Christopher J. Howlett, Paul Plantinga, Matthew J. Cecchini, Alfred K. Lam, Iram Siddiqui, Jianxin Wang, Ren X.
    Cell Reports.2024; 43(3): 113826.     CrossRef
  • Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation
    Kun Zhang, Xinyi Wang, Tao Wei, Zhihui Li, Jingqiang Zhu, Ya-Wen Chen
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer – Real-World Outcomes From UK Centres
    C. Lorimer, L. Cheng, R. Chandler, K. Garcez, V. Gill, K. Graham, W. Grant, S. Sardo Infirri, J. Wadsley, L. Wall, N. Webber, K.H. Wong, K. Newbold
    Clinical Oncology.2023; 35(1): e60.     CrossRef
  • MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions
    E. Macerola, A. M. Poma, P. Vignali, A. Proietti, L. Torregrossa, C. Ugolini, A. Basolo, A. Matrone, R. Elisei, F. Santini, F. Basolo
    Journal of Endocrinological Investigation.2023; 46(8): 1651.     CrossRef
  • RBX1 regulates PKM alternative splicing to facilitate anaplastic thyroid carcinoma metastasis and aerobic glycolysis by destroying the SMAR1/HDAC6 complex
    Debin Xu, Jichun Yu, Yuting Yang, Yunyan Du, Hongcheng Lu, Shouhua Zhang, Qian Feng, Yi Yu, Liang Hao, Jun Shao, Leifeng Chen
    Cell & Bioscience.2023;[Epub]     CrossRef
  • Multi-Omics and Management of Follicular Carcinoma of the Thyroid
    Thifhelimbilu Emmanuel Luvhengo, Ifongo Bombil, Arian Mokhtari, Maeyane Stephens Moeng, Demetra Demetriou, Claire Sanders, Zodwa Dlamini
    Biomedicines.2023; 11(4): 1217.     CrossRef
  • Genomic landscape of anaplastic thyroid cancer and implications on therapy
    Leslie Cheng, Kate Newbold
    Current Opinion in Endocrine and Metabolic Research.2023; 30: 100458.     CrossRef
  • Modeling the tumor microenvironment of anaplastic thyroid cancer: an orthotopic tumor model in C57BL/6 mice
    Zhen Xu, Hyo Shik Shin, Yoo Hyung Kim, Seong Yun Ha, Jae-Kyung Won, Su-jin Kim, Young Joo Park, Sareh Parangi, Sun Wook Cho, Kyu Eun Lee
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Characterization of the genomic alterations in poorly differentiated thyroid cancer
    Yeeun Lee, SeongRyeol Moon, Jae Yeon Seok, Joon-Hyop Lee, Seungyoon Nam, Yoo Seung Chung
    Scientific Reports.2023;[Epub]     CrossRef
  • Genetica del carcinoma anaplastico della tiroide
    Teresa Ramone, Chiara Mulè, Cristina Romei, Raffaele Ciampi, Eleonora Molinaro, Rossella Elisei
    L'Endocrinologo.2022; 23(2): 208.     CrossRef
  • Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology
    Elena Muraro, Rebecca Romanò, Giuseppe Fanetti, Emanuela Vaccher, Irene Turturici, Valentina Lupato, Fabio Biagio La Torre, Jerry Polesel, Elisabetta Fratta, Vittorio Giacomarra, Giovanni Franchin, Agostino Steffan, Michele Spina, Salvatore Alfieri
    Critical Reviews in Oncology/Hematology.2022; 175: 103707.     CrossRef
  • Recent Improvements in the Treatment of High-Risk Thyroid Cancer
    Eun Kyung Lee
    Korean Society for Head and Neck Oncology.2022; 38(1): 1.     CrossRef
  • Inhibition of Glycogen Metabolism Induces Reactive Oxygen Species-Dependent Cytotoxicity in Anaplastic Thyroid Cancer in Female Mice
    Cole D Davidson, Jennifer A Tomczak, Eyal Amiel, Frances E Carr
    Endocrinology.2022;[Epub]     CrossRef
  • Survival prognostic factors for differentiated thyroid cancer patients with pulmonary metastases: A systematic review and meta-analysis
    Hao Zhao, Chun-Hao Liu, Yue Cao, Li-Yang Zhang, Ya Zhao, Yue-Wu Liu, Hong-Feng Liu, Yan-Song Lin, Xiao-Yi Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
    Keith C. Bible, Electron Kebebew, James Brierley, Juan P. Brito, Maria E. Cabanillas, Thomas J. Clark, Antonio Di Cristofano, Robert Foote, Thomas Giordano, Jan Kasperbauer, Kate Newbold, Yuri E. Nikiforov, Gregory Randolph, M. Sara Rosenthal, Anna M. Saw
    Thyroid.2021; 31(3): 337.     CrossRef
  • Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine
    Antonio Ieni, Roberto Vita, Cristina Pizzimenti, Salvatore Benvenga, Giovanni Tuccari
    Journal of Personalized Medicine.2021; 11(5): 333.     CrossRef
  • The Role of Altered Mitochondrial Metabolism in Thyroid Cancer Development and Mitochondria-Targeted Thyroid Cancer Treatment
    Siarhei A. Dabravolski, Nikita G. Nikiforov, Alexander D. Zhuravlev, Nikolay A. Orekhov, Liudmila M. Mikhaleva, Alexander N. Orekhov
    International Journal of Molecular Sciences.2021; 23(1): 460.     CrossRef
  • Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E
    Young Shin Song, Young Joo Park
    Endocrinology and Metabolism.2020; 35(3): 515.     CrossRef
Close layer
Namgok Lecture 2018
Thyroid
Genomic Characterization of Differentiated Thyroid Carcinoma
Young Shin Song, Young Joo Park
Endocrinol Metab. 2019;34(1):1-10.   Published online March 21, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.1.1
  • 7,096 View
  • 210 Download
  • 36 Web of Science
  • 36 Crossref
AbstractAbstract PDFPubReader   ePub   

Since the release of The Cancer Genome Atlas study of papillary thyroid carcinoma (PTC) in 2014, additional genomic studies of differentiated thyroid carcinoma (DTC) using massively-parallel sequencing (MPS) have been published. Recent advances in MPS technology have started to provide important insights into the molecular pathogenesis of DTC. In the genomic landscape, the most recurrently altered genes in DTC, which has a low mutational burden relative to other cancers, are BRAF, RAS, and fusion genes. Some novel driver candidates also have been identified. The frequency of these genomic alterations varies across the subtypes of DTC (classical PTC, follicular variant of PTC, and follicular thyroid carcinoma). Telomerase reverse transcriptase (TERT) promoter mutations are the alteration that makes the most important contribution to the progression of DTC. In the transcriptomic landscape, DTC can be classified according to its gene expression profile, and each subtype has a distinct mutational profile, intracellular signaling output, and clinicopathological characteristics. Herein, we review the results of genomic studies using MPS technology, and describe the types and frequencies of genomic alterations according to histological classifications of DTC and the characteristics and significance of the gene expression signatures of DTC.

Citations

Citations to this article as recorded by  
  • Radiation-Related Thyroid Cancer
    Vladimir Saenko, Norisato Mitsutake
    Endocrine Reviews.2024; 45(1): 1.     CrossRef
  • TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases
    Marie-Lisa Eich, Wiebke Jeske, Uschi Zenz, Costanza Chiapponi, Christina Alidousty, Sabine Merkelbach-Bruse, Reinhard Büttner, Anne M. Schultheis
    Thyroid Research.2024;[Epub]     CrossRef
  • Molecular testing in fine‐needle aspiration of thyroid nodules
    Valarie McMurtry, Sule Canberk, Georgios Deftereos
    Diagnostic Cytopathology.2023; 51(1): 36.     CrossRef
  • A Triumvirate:
    Jaylou M. Velez Torres, Youley Tjendra, Darcy A. Kerr
    Surgical Pathology Clinics.2023; 16(1): 1.     CrossRef
  • Current Status and Prospects of Chemotherapy in Treatment of Distant Metastatic or Recurrent Thyroid Cancer
    T. Yamazaki
    Nihon Kikan Shokudoka Gakkai Kaiho.2023; 74(2): 141.     CrossRef
  • FDG uptake reflects an immune‐enriched subtype of thyroid cancer: Clinical implications of imaging‐based molecular characterization
    Hoon Young Suh, Hongyoon Choi, Sun Wook Cho, Jin Chul Paeng, Gi Jeong Cheon, Young Joo Park, Keon Wook Kang
    Cancer Medicine.2023; 12(16): 17068.     CrossRef
  • Advances in transcriptomics and proteomics in differentiated thyroid cancer: An updated perspective (Review)
    Shici Yang, Gaohong Zhu, Rui He, Dong Fang, Jiaojiao Feng
    Oncology Letters.2023;[Epub]     CrossRef
  • Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma
    Jinsun Lim, Han Sai Lee, Jiyun Park, Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho, Young Shin Song
    Endocrinology and Metabolism.2023; 38(4): 445.     CrossRef
  • Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review)
    Abdul-Mohsen Alhejaily, Omar Alhuzim, Yazeed Alwelaie
    Molecular and Clinical Oncology.2023;[Epub]     CrossRef
  • Comparative Analysis of Driver Mutations and Transcriptomes in Papillary Thyroid Cancer by Region of Residence in South Korea
    Jandee Lee, Seonhyang Jeong, Hwa Young Lee, Sunmi Park, Meesson Jeong, Young Suk Jo
    Endocrinology and Metabolism.2023; 38(6): 720.     CrossRef
  • Problems of follicular thyroid carcinoma diagnostics
    S. E. Titov, S. A. Lukyanov, S. V. Sergiyko, Yu. A. Veryaskina, T. E. Ilyina, E. S. Kozorezov, S. L. Vorobyov
    Head and Neck Tumors (HNT).2023; 13(3): 10.     CrossRef
  • Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies
    María San Román-Gil, Javier Pozas, Diana Rosero-Rodríguez, Jesús Chamorro-Pérez, Álvaro Ruiz-Granados, Ignacio Ruz Caracuel, Enrique Grande, Javier Molina-Cerrillo, Teresa Alonso-Gordoa
    Cancer Treatment Reviews.2022; 105: 102372.     CrossRef
  • Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology
    Myat Han Soe, Janet M Chiang, Robert R Flavell, Elham Khanafshar, Laura Mendoza, Hyunseok Kang, Chienying Liu
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(8): e3206.     CrossRef
  • Recent Improvements in the Treatment of High-Risk Thyroid Cancer
    Eun Kyung Lee
    Korean Society for Head and Neck Oncology.2022; 38(1): 1.     CrossRef
  • Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles
    Ahreum Jang, Meihua Jin, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Yu-Mi Lee, Won Gu Kim
    Annals of Surgical Oncology.2022; 29(12): 7835.     CrossRef
  • Tackling Thyroid Cancer in Europe—The Challenges and Opportunities
    Denis Horgan, Dagmar Führer-Sakel, Paula Soares, Clara V. Alvarez, Laura Fugazzola, Romana T. Netea-Maier, Barbara Jarzab, Marta Kozaric, Beate Bartes, James Schuster-Bruce, Luigino Dal Maso, Martin Schlumberger, Furio Pacini
    Healthcare.2022; 10(9): 1621.     CrossRef
  • The role of EZH1 and EZH2 in development and cancer
    Soo Hyun Lee, Yingying Li, Hanbyeol Kim, Seounghyun Eum, Kyumin Park, Chul-Hwan Lee
    BMB Reports.2022; 55(12): 595.     CrossRef
  • The mutation profile of differentiated thyroid cancer coexisting with undifferentiated anaplastic cancer resembles that of anaplastic thyroid cancer but not that of archetypal differentiated thyroid cancer
    Justyna Mika, Wojciech Łabaj, Mykola Chekan, Agata Abramowicz, Monika Pietrowska, Andrzej Polański, Piotr Widłak
    Journal of Applied Genetics.2021; 62(1): 115.     CrossRef
  • Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer
    Ying Wang, Zhigang Hu, Weiyuan Ma, Yong Niu, Jingwei Su, Lingxiang Zhang, Pengxin Zhao
    Investigational New Drugs.2021; 39(3): 764.     CrossRef
  • Thyroid Cancer Identified After Positron Emission Tomography (PET) Shows Aggressive Histopathology
    Tim Beck, Ning Zhang, Akeesha Shah, Sarah Khoncarly, Christopher McHenry, Judy Jin
    Journal of Surgical Research.2021; 260: 245.     CrossRef
  • Associations between artificial light at night and risk for thyroid cancer: A large US cohort study
    Dong Zhang, Rena R. Jones, Peter James, Cari M. Kitahara, Qian Xiao
    Cancer.2021; 127(9): 1448.     CrossRef
  • Association of Hyperparathyroidism and Papillary Thyroid Cancer: A Multicenter Retrospective Study (Endocrinol Metab 2020;35:925-32, Chaiho Jeong et al.)
    Chaiho Jeong, Jeonghoon Ha, Moo Il Kang
    Endocrinology and Metabolism.2021; 36(1): 205.     CrossRef
  • Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine
    Antonio Ieni, Roberto Vita, Cristina Pizzimenti, Salvatore Benvenga, Giovanni Tuccari
    Journal of Personalized Medicine.2021; 11(5): 333.     CrossRef
  • Silencing circRNA protein kinase C iota (circ-PRKCI) suppresses cell progression and glycolysis of human papillary thyroid cancer through circ-PRKCI/miR-335/E2F3 ceRNA axis
    Yan Liu, Gen Chen, Bo Wang, Hanjin Wu, Yi Zhang, Hui Ye
    Endocrine Journal.2021; 68(6): 713.     CrossRef
  • Multiparametric Photoacoustic Analysis of Human Thyroid Cancers In Vivo
    Jeesu Kim, Byullee Park, Jeonghoon Ha, Idan Steinberg, Sarah M. Hooper, Chaiho Jeong, Eun-Yeong Park, Wonseok Choi, Tie Liang, Ja Seong Bae, Ravi Managuli, Yongmin Kim, Sanjiv S. Gambhir, Dong-Jun Lim, Chulhong Kim
    Cancer Research.2021; 81(18): 4849.     CrossRef
  • Thyroid Cancer Risk Factors in Children with Thyroid Nodules: A One-Center Study
    Iwona Ben-Skowronek, Joanna Sieniawska, Emilia Pach, Wiktoria Wrobel, Anna Skowronek, Zaklina Tomczyk, Anna Mlodawska, Magdalena Makuch, Magdalena Malka, Czeslaw Cielecki, Pawel Nachulewicz
    Journal of Clinical Medicine.2021; 10(19): 4455.     CrossRef
  • Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers
    Rita Niciporuka, Jurijs Nazarovs, Arturs Ozolins, Zenons Narbuts, Edvins Miklasevics, Janis Gardovskis
    Medicina.2021; 57(10): 1131.     CrossRef
  • Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers
    Seong-Keun Yoo, Young Shin Song, Young Joo Park, Jeong-Sun Seo
    Endocrinology and Metabolism.2020; 35(1): 44.     CrossRef
  • Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma
    Young Shin Song, Byung-Hee Kang, Seungbok Lee, Seong-Keun Yoo, Young Sik Choi, Jungsun Park, Dong Yoon Park, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
    Cancers.2020; 12(5): 1345.     CrossRef
  • Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Diagnostic updates and molecular advances
    Ying-Hsia Chu, Peter M. Sadow
    Seminars in Diagnostic Pathology.2020; 37(5): 213.     CrossRef
  • Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy
    María San Román Gil, Javier Pozas, Javier Molina-Cerrillo, Joaquín Gómez, Héctor Pian, Miguel Pozas, Alfredo Carrato, Enrique Grande, Teresa Alonso-Gordoa
    International Journal of Molecular Sciences.2020; 21(14): 4951.     CrossRef
  • DNA FISH Diagnostic Assay on Cytological Samples of Thyroid Follicular Neoplasms
    Philippe Vielh, Zsofia Balogh, Voichita Suciu, Catherine Richon, Bastien Job, Guillaume Meurice, Alexander Valent, Ludovic Lacroix, Virginie Marty, Nelly Motte, Philippe Dessen, Bernard Caillou, Abir Ghuzlan, Jean-Michel Bidart, Vladimir Lazar, Paul Hofma
    Cancers.2020; 12(9): 2529.     CrossRef
  • Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E
    Young Shin Song, Young Joo Park
    Endocrinology and Metabolism.2020; 35(3): 515.     CrossRef
  • Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China
    Yuntao Song, Guohui Xu, Tonghui Ma, Yanli Zhu, Hao Yu, Wenbin Yu, Wei Wei, Tianxiao Wang, Bin Zhang
    Cancer Medicine.2020; 9(22): 8397.     CrossRef
  • Thyroid Cancer and Circadian Clock Disruption
    Roberta Malaguarnera, Caterina Ledda, Agnese Filippello, Francesco Frasca, Vincenzo Cristian Francavilla, Tiziana Ramaci, Maria Chiara Parisi, Venerando Rapisarda, Salvatore Piro
    Cancers.2020; 12(11): 3109.     CrossRef
  • Molecular testing approaches in thyroid cancer diagnosis
    Abdul-Mohsen AlHejaily, Naji AlJohani
    Journal of Biochemical and Clinical Genetics.2020; : 77.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism